conducted an evaluation of donor CD19 CAR‐T therapy in 43 patients with relapsed CD19+ B‐cell acute lymphoblastic leukemia (B‐ALL) following allo‐HSCT.[47] This study demonstrated the safety and efficacy of this approach, with 34 patients achieving complete remission (CR). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.